* Directors / Signatories / KMP / Principals


Company Status: Amalgamated As on: 06-Aug-2019

D&B Summary

Paid-up Capital(INR)
Authorised Capital(INR)
Total Charges(INR)
Open Charges(INR)
D&B Reports
Basic Report
INR 6000.00 /-
Report Status : Available
Financial Year : N/A
Quick Check Report
INR 2500.00 /-
Report Status : Available
Financial Year : N/A
Compliance Report
INR 14000.00 /-
Report Status : Available
Financial Year : N/A
Sectoral Risk Outlook (Industry Report)
Sectoral Risk Outlook (Industry Report) Status : Unavailable
Financial Year : NA
Business of interest
Low High
No. of search on company
80% Complete

Global Inhalation And Nasal Spray Generic Drugs Market Growth Outlook 2015-2027 By- Ranbaxy Laboratories Ltd., Novartis AG (Sandoz International GmbH), Cipla Ltd., Nephron Pharmaceuticals Corporation, Allergan plc - SoccerNurds

Global Imipenem and Cilastatin Sodium Market 2025 by Trends, Strategies and Growth by leading Manufacturers High Science Co.,Ltd., Shenzhen Haibin Pharmaceutical, Savior Lifetec Corporation, Ranbaxy Laboratories, Ranbaxy Laboratories Ltd - The Bisouv Network

Global Alopecia Treatment (Hair Loss) Market 2021: Global Industry Expand with Significant CAGR by 2028|| Top Competitors- Cipla,Viviscal,Dr. Reddy's Laboratories Ltd.,Regaine,Merck & Co., Inc,Ranbaxy Laboratories Ltd - South Florida Theater Review

Global Enalapril Market 2021 Recovering From Covid-19 Outbreak | Know About Brand Players: Apotex Inc, Sandoz Inc, Krka Dd Novo Mesto, Apothecon Inc Div Bristol Myers Squibb, Ranbaxy Laboratories Ltd, etc. | InForGrowth - NeighborWebSJ

Hair Loss and Growth Treatments and Products Market (COVID-19) to Witness Astonishing Growth by Forecast 2021-2027 |Cipla, Viviscal, Regaine, Merck & Co., Inc, etc - NeighborWebSJ

Global Alopecia Market for robust expansion throughout the forecast period 2020-2026 – NeighborWebSJ - NeighborWebSJ

Global API Contract Manufacturing Market Focuses on SWOT analysis, Industry Synopsis, Development Plans 2021 to 2026 – NeighborWebSJ - NeighborWebSJ

Erythropoietin Stimulating Agents Market Future Scenario, Growth rate, Market Segmentation, and Industrial Opportunities to 2027 – The Bisouv Network - The Bisouv Network

Global Alopecia Treatment (Hair Loss) Market Set To Boom With Top Booming Companies-Dr. Reddy's Laboratories Ltd.,Regaine,Merck & Co., Inc,Ranbaxy Laboratories Ltd,Phyto – Alès Groupe - The Courier

Barotrauma Market Advancing the Growth Globally: Market Dynamics, Trends, Efficiencies Forecast 2026 - NeighborWebSJ

Inhalation And Nasal Spray Generic Drugs Market: Industry Analysis And Forecast 2026 – The Bisouv Network - The Bisouv Network

Hair Loss Treatment Products Market Size 2021 | Global Industry Share, Trends, Growth Insights, SWOT Analysis by Top Key Vendors and Forecast to 2027 - The Bisouv Network

Global Enalapril Industry Research Report, Growth Trends and Competitive Analysis 2021-2027| Apotex Inc, Apothecon Inc Div Bristol Myers Squibb, Ivax Pharmaceuticals Inc Sub Teva Pharmaceuticals Usa - SoccerNurds

Controversy swirls around India’s homegrown Covid vaccine - Mint

Androgenetic Alopecia Treatment Market will Explore Robust Size & Growth During 2018-2026 – NY Market Reports - NY Market Reports

Generic Drugs Market 2020-2026 By Application, By Product Type, Top Key Players: Ranbaxy Laboratories, Ltd, Actavis, Mylan Inc., Teva Pharmaceutical Industries, Ltd., Dr. Reddy’s Laboratories - The Courier

API Contract Manufacturing Market Size 2021 | Global Industry Analysis, Development, Scope, Trends, Forecast to 2027 – Express Keeper - Express Keeper

Botanical and Plant-Derived Drugs Market 2021 Focusing on Top Key Players like Abbott Laboratories, Eli Lilly, Medigene, Pfizer, Lupin Ltd., Johnson & Johnson, Ranbaxy Laboratories Ltd., Novartis International AG, Glaxosmithkline and Leo Pharma - The Courier

India's Sun Pharma to buy struggling Ranbaxy for $3.2 billion as Daiichi Sankyo retreats - Reuters

U.S. class action asserts India's Ranbaxy manipulated FDA rules - Reuters

Ranbaxy shares to stop trading on exchanges from 6 April - Livemint

Sun Pharma buys Ranbaxy to create generics giant - Livemint

Singapore court rejects Singh brothers' plea against arbitral award in Daiichi case - VCCircle

Ranbaxy Laboratories posts Rs160 crore loss in Dec quarter - Livemint

Global Alopecia Treatment (Hair Loss) Market Regional Overview, Leading Company Analysis And Forecast To 2026 | Dr. Reddy's Laboratories Ltd.,Regaine,Merck & Co., Inc,Ranbaxy Laboratories Ltd,Phyto – Alès Groupe - The Courier

Ex-Ranbaxy owners told to pay Rs2,500 crore for hiding facts in Daiichi sale - Livemint

Six business lessons from the Daiichi–Ranbaxy deal fiasco - Livemint

Ranbaxy pleads guilty, to pay $500 million in U.S. settlement - Reuters

Ranbaxy And The Culture Of Jugaad: What Brought A Leading Company Down - Outlook India

Ranbaxy agrees to $4 billion buyout - Jacksonville Daily Record

Ranbaxy agrees to $4 billion buyout  Jacksonville Daily Record

Ranbaxy to contest US pharma company to protect drug patent - Hindu Business Line

Making Ranbaxy units cGMP compliant time consuming: Sun Pharma - Livemint

How Ranbaxy hurtled towards a meltdown - Livemint

Ranbaxy recalls some batches of generic Lipitor in latest quality blow - Reuters

Ranbaxy scrambles for ingredients to make generic Nexium - Reuters

Sun Pharma sells Ranbaxy divisions to Strides Arcolab for Rs165 crore - Livemint

Daiichi-Ranbaxy row: Delhi HC restrains Singh brothers from using bank a/cs - Livemint

FDA may inspect one Ranbaxy plant in fiscal 2017: Dilip Shanghvi - Livemint

Ranbaxy puts biosimilars into gear - Reuters

Sun Pharma Took Two Years To Integrate Ranbaxy’s Employees - BW Businessworld

FDA Says Ranbaxy Can’t Make Generic Versions of Nexium, Valcyte - Wall Street Journal

Daiichi-Ranbaxy row: HC allows the sale of Singh brothers firms to repay the Rs 3,500 crore arbitration... - Medical Dialogues

Ranbaxy Laboratories posts surprise March-quarter loss on write-offs - indiatvnews.com

Sun Pharma’s Mohali unit violated manufacturing norms, finds US FDA - Livemint

Religare group emerges out of Ranbaxy shadow - Livemint

Ranbaxy gets FDA approval for Novartis's Diovan generic - Reuters India

Ranbaxy fallout: Indian pharma under the microscope - Livemint

Sun Pharma shares soar as Ranbaxy to delist - Livemint

Ranbaxy in licensing pact with Gilead Sciences for HIV drug - Hindu Business Line

Truth behind FDA ban on Ranbaxy found: Human hair embedded in tablet - Firstpost

The rise and fall of Singh brothers' business empire - CNBCTV18

Sun Pharma warns on revenue, profit over Ranbaxy takeover - Livemint

FDA bans imports from Sun Pharma plant in India crackdown - Reuters

Sun Pharma, Ranbaxy shares decline after court stalls merger - Livemint

The CEO who capped a $37 billion recovery with a cancer drug deal - Livemint

Ranbaxy shares crash as Mohali plant comes under FDA scanner - Livemint

Ranbaxy’s US plant gets FDA clearance - Livemint

Competition Commission extends Sun Pharma-Ranbaxy probe to new stage - Livemint

Ranbaxy and Teva settle with NY Attorney General over collusion - Reuters

Sun Pharma hikes stake in Zenotech to 57.56% - VCCircle

Sun Pharmaceutical withdraws suit filed by Ranbaxy against USFDA - Business Today

Culture of 'Bending Rules' in India Challenges U.S. Drug Agency - Bloomberg

All’s Not Well In Sun Pharma-Ranbaxy Human Resource Integration? - BloombergQuint

Ranbaxy Wins Approval for Generic Blood-Pressure Drug Diovan - Wall Street Journal

SC gives Andhra Pradesh HC two days to decide Sun-Ranbaxy issue - Livemint

Petition against Sun Pharma for allegedly violating merger norms - Livemint

Singh brothers, ex-promoters of Ranbaxy held in Rs 740 crore fraud | What the case is all about - Jagran English

FDA bans Ranbaxy’s fourth plant in India - The Hindu

Ranbaxy resumes supply of Atorvastatin tablets in US market - The Hindu

Sun Pharma-Ranbaxy Laboratories deal comes under CCI scanner - indiatvnews.com

Sun Pharma denies wrongdoing, says some issues are factually incorrect - Livemint

Ranbaxy makes good on its promise - Livemint

Pfizer, Ranbaxy win lawsuit over generic Lipitor - Deccan Herald

High Court approves merger of Sun Pharma, Ranbaxy - Equity Bulls

Ranbaxy posts profit in July-Sept quarter - MarketWatch

CCI clears Sun-Ranbaxy deal with some riders - Livemint

Domestic M&As surge to a four-year high in 2014 - Livemint

Fortis shareholders vote out former Ranbaxy CEO Brian Tempest as director - VCCircle

Sun Pharma-Ranbaxy merger: Honeymoon over, now to make it work - Livemint

Ranbaxy Laboratories dips nearly 7% on bourses - Livemint

Ranbaxy’s performance hinges on generic Diovan - Livemint

Ranbaxy accused of gaming FDA rules to thwart rival drug makers - Livemint

Daiichi Sankyo sells entire 8.9% stake in Sun Pharma for $3.18B; Temasek, GIC among buyers - VC Circle

Sun Pharma asked to pay Rs 279 crore GST dues on Ranbaxy arbitration - CNBCTV18

Sobti quits Ranbaxy over differences with management - The Hindu

Ranbaxy Labs Narrows Losses - Wall Street Journal

Ranbaxy Labs Narrows Losses  Wall Street Journal

How Singh brothers got into trouble - bit by bit - Business Today

Singh brothers sent to 14 days judicial custody in Religare case - Livemint

Open offer for Zenotech fails to meet target - Livemint

Sun Pharma-Ranbaxy merger gets BSE, NSE clearance - Livemint

Fortis tries to leave its past behind by seeking to rebrand as Parkway - VCCircle

‘Bottle of Lies’: Book on Generic Drugs ‘Exposes’ Indian Companies - The Quint

Delhi HC allows Daiichi Sankyo to recover Rs3,500 crore from Singh brothers - Livemint

Know 5 things before buying Sun Pharma shares - Economic Times

Andhra HC lifts stay on Sun Pharma-Ranbaxy merger - VC Circle

Ranbaxy case: SC rejects plea by Singh brothers against Daiichi Sankyo’s Rs3,500 crore award - Livemint

FDA bans imports from canadian drugmaker Apotex’s India plant - Livemint

Class Certification Denied in Suit Over Adulterated Ranbaxy Drugs | New Jersey Law Journal - Law.com

Ranbaxy halts drug ingredients shipment from Toansa, Dewas plants - Livemint

Ranbaxy keeps sales forecast as India reviews US court ruling - Livemint

Company Details



ROC Code


Date of Incorporation


D&B D-U-N-S® Number


Company Category

Company limited by Shares

Company SubCategory

Non-govt company

Class of Company




Authorised Capital( INR)


Paid up Capital( INR)


Number of Members


Registered Address

A-41 Industrial Area Phase VIII-A SAS Nagar PB 160071 IN

Email Id


Whether Listed or not


Last AGM


Last Balance Sheet


Registration Number



Potentially Related Company Based on Common Directorship


Charge Holder Name Assets under charge Charge Amount Date of Creation Date of Modification Status

Principals/Signatory Details

Identification Number Principal Names Designation Begin date End date
00021752 RAJESH VIREN SHAH Director 19/12/2008 13/10/2020
01929668 ARUN SAWHNEY Managing Director 09/05/2011 02/10/2020
02143003 PERCY KEKU SHROFF Director 27/03/2009 22/07/2021
02436813 TAKASHI SHODA Director 19/12/2008 -
02439360 AKIHIRO WATANABE Director 19/12/2008 05/10/2020
02439401 TSUTOMU UNE Director 19/12/2008 13/10/2020
02454431 ANTHONY HUGH WILD Director 19/12/2008 -
03562763 KAZUNORI HIROKAWA Director 09/05/2012 27/06/2012
XXXXXXXXXX SUSHIL KUMAR PATAWARI Company Secretary 21/09/1995 09/12/2016

Corporate Family Connections

Detailed profiles of all businesses owned and operated by this company for insights and prospecting.

51 Subsidiaries

0 Branches

2 Affiliates

Company network based on common directorship

© 2021 - Dun & Bradstreet Information Services India Pvt Ltd. All rights reserved.